Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $45 | $34 | $29 | $28 |
| % Growth | 32% | 19.6% | 0.8% | – |
| Cost of Goods Sold | $8 | $7 | $7 | $7 |
| Gross Profit | $37 | $27 | $22 | $21 |
| % Margin | 81.3% | 79.2% | 76.8% | 74.2% |
| R&D Expenses | $11 | $9 | $7 | $7 |
| G&A Expenses | $8 | $7 | $6 | $6 |
| SG&A Expenses | $8 | $7 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19 | $16 | $13 | $13 |
| Operating Income | $18 | $11 | $9 | $8 |
| % Margin | 38.9% | 31.6% | 30.3% | 28% |
| Other Income/Exp. Net | -$5 | -$4 | -$2 | -$2 |
| Pre-Tax Income | $13 | $7 | $7 | $6 |
| Tax Expense | $2 | $1 | $1 | $1 |
| Net Income | $11 | $5 | $6 | $6 |
| % Margin | 23.5% | 15.4% | 21.9% | 19.7% |
| EPS | 11.76 | 5.83 | 6.57 | 5.85 |
| % Growth | 101.7% | -11.3% | 12.3% | – |
| EPS Diluted | 11.71 | 5.8 | 6.57 | 5.85 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | $15 | $9 | $9 | $8 |
| % Margin | 33.8% | 25.1% | 30.3% | 28.4% |